Editorials

Pneumococcal Vaccination Strategies in the Real World of Chronically Ill Patients
N.M. Wulffraat, M.W. Heijstek ........................................... 255

MCID — The Minimal Clinically Important Difference Assigns Significance to Outcome Effects
F. Angst ................................................................. 258

Review

The Genetic Epidemiological Landscape of Hip and Knee OA: Where Are We Now and Where Are We Going?
E. Zengini, C. Finan, J.M. Wilkinson .................................. 260

Articles

Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases
A. Broyde, U. Arad, N. Madar-Balakirski, et al. ....................... 267

Anti-carbamylated Protein Antibody Levels Correlate with Anti-Sa (Citrullinated Vimentin) Antibody Levels in RA

A Prospective Study Investigating Prediagnostic Leukocyte Telomere Length and Risk of Developing RA in Women
J. Prescott, E.W. Karlson, E.H. Orr, R.Y. Zee,
I. De Vivo, K.H. Costenbader ............................................ 282

Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with RA
M.C. Genovese, D.K. Braun, J.S. Erickson, et al. ..................... 289

Safety and Efficacy of Subcutaneous Golimumab in Patients with Active RA despite MTX Therapy: Final 5-year Results of the GO-FORWARD Trial

Physical and Mental Functioning in Patients with Established RA over an 11-year Followup Period: The Role of Specific Comorbidities
J. van den Hoek, L.D. Roorda, H.C. Boshuizen,
G.J. Tijhuis, G.A. van den Bos, J. Dekker ................................ 307

Coronary, Carotid, and Lower-extremity Atherosclerosis and Their Interrelationship in Danish Patients with SLE
S.D. Kay, M.K. Poulsen, A.C. Diederichsen, A. Voss ................ 315

Pulmonary Arterial Hypertension in SLE: Prevalence and Predictors G.M. Pérez-Pérolte, I. Rúa-Figueroa,
G. Juliá-Serdà, et al. ...................................................... 323

Radiologic Changes in the Symphys Pubis of Male Patients with Ankylosing Spondylitis
B.S. Koo, Y. Song, K.B. Joo, S. Lee, T.H. Kim ......................... 330

Whole Body MRI Features in Diffuse Idiopathic Skeletal Hyperostosis in Conjunction with Clinical Variables to Whole Body MRI and Clinical Variables in AS
B.G. Weiss, L.M. Bachmann, C.W. Pfirrmann,
R.O. Kissling, V. Zubler ................................................ 335

Improvement in PsO Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with PsA
P.J. Mease, M.C. Genovese, A. Mutebi, et al ......................... 343

Minimal Disease Activity and Remission in PsA Patients Treated with Anti-TNF-α Drugs
F.M. Perrotta, A. Marchesoni, E. Lubrano .......................... 350

MTX Efficacy in the Tight Control in PsA Study
L.C. Coates, P.S. Helliwell ............................................. 356

The Incidence and Predictors of Infection in PsO and PsA: Results from Longitudinal Observational Cohorts
A. Haddad, S. Li, A. Thavaneswaran, R.J. Cook,
V. Chandran, D.D. Gladman ........................................... 362

Novel Composite Radiographic Score for Longitudinal Observational Studies of PsA: A Proof-of-concept Study
W. Tillett, G. Shaddick, D. Jadon, G. Robinson,
E. Korendowych, N. McHugh ........................................ 367

Defining Low Disease Activity States in PsA using Novel Composite Disease Instruments
L.C. Coates, P.S. Helliwell ............................................. 371

Comorbidities Associated with PsA Compared with Non-psoriatic SpA: A Cross-sectional Study
N. Haque, R.J. Lories, K. de Vlam .................................... 376

Obesity Is Common in Axial SpA and Is Associated with Poor Clinical Outcome
F. Maas, S. Arends, E. van der Veer, et al. ............................ 383

Contents continued on page xx
Images in Rheumatology
A Portrait of Juvenile Arthritis with Multiple Joint Abnormalities M.A. Kapusta 450
Facial Rash following Infliximab Treatment N.N. Carmel, Y. Levy 452

Correspondence
What is the Significance of Change of Cutpoint from 13 to 12 If Polysymptomatic Distress Is Not a Diagnostic Criterion? K. Toda 453
Reply F. Wolfe 453
The Polysymptomatic Distress Scale Is Simple, Useful, and Effective in Clinical Care and Clinical and Epidemiology Studies F. Wolfe, B.T. Walitt, J.J. Rasker, R.S. Katz, W. Häuser 454
Reply R. Friend, R.M. Bennett 455

Letters
Cytomegalovirus-induced Colon Perforation in SLE T. Glushko, V.A. Marcus, I. Colmegna 459
An Unexpected Cause of Tenosynovitis L. Chou, J. Day, S. Ciciriello 461
Higher Prevalence of the Metabolic Syndrome in Patients with PsA: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions M. Haroon, A. Bin Rafiq Chaudhry, O. Fitzgerald 463

Meetings in Rheumatology